Search Result

Results for "

MDMs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Aminopeptidase (1) AMPK (1) Apoptosis (59) Autophagy (9) Bcl-2 Family (5) Biochemical Assay Reagents (1) c-Myc (5) Calcium Channel (1) Casein Kinase (2) Caspase (7) CDK (2) COX (1) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (1) Cytochrome P450 (1) DAPK (1) Deubiquitinase (7) Dihydroorotate Dehydrogenase (1) DNA Methyltransferase (1) Drug Derivative (3) Drug Intermediate (2) Drug Isomer (4) Drug-Linker Conjugates for ADC (1) DYRK (1) E1/E2/E3 Enzyme (46) E3 Ligase Ligand-Linker Conjugates (6) Early 2 Factor (E2F) (1) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (3) Ferroptosis (1) FLAP (2) Fluorescent Dye (3) Fungal (3) HDAC (3) Herbicide (2) Histone Methyltransferase (1) HIV (1) IAP (3) IGF-1R (1) IKZF Family (1) Integrin (1) Interleukin Related (3) IRAK (1) Isotope-Labeled Compounds (4) JAK (1) JNK (1) Ligands for E3 Ligase (8) Ligands for Target Protein for PROTAC (4) Lipoxygenase (1) LPL Receptor (1) MAGL (1) MDM-2/p53 (170) Mixed Lineage Kinase (1) NADH Dehydrogenase (1) NF-κB (3) Notch (1) Opioid Receptor (1) Parasite (1) PARP (5) PDK-1 (1) PI3K (2) Pim (1) PROTACs (20) PTEN (1) Reactive Oxygen Species (ROS) (2) Reference Standards (7) Reverse Transcriptase (1) Sirtuin (1) Small Interfering RNA (siRNA) (10) STAT (2) Target Protein Ligand-Linker Conjugates (10) TGF-beta/Smad (1) TNF Receptor (2) Topoisomerase (3) Wnt (1) β-catenin (2)
By Research Areas:	Cancer (214) Cardiovascular Disease (2) Endocrinology (1) Infection (5) Inflammation/Immunology (11) Neurological Disease (9)
Click Chemistry:	PROTAC Synthesis (1) Azide (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (3) Mouse Pre-designed siRNA Sets (4) Human Pre-designed siRNA Sets (3) Antisense Oligonucleotides (4) siRNAs (10)

243

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0175

740 Y-P 240+ Cited Publications 740YPDGFR; PDGFR 740Y-P	PI3K Autophagy	Cancer
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

HY-50696

Nutlin-3 40+ Cited Publications	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Nutlin-3 is a commercial available *p53-MDM2* inhibitor, with K_i of 90 nM.

HY-15676

Idasanutlin 50+ Cited Publications RG7388	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Idasanutlin (RG7388) is a potent and selective *MDM2* antagonist, inhibiting p53-MDM2 binding, with an IC₅₀ of 6 nM.

HY-152859

Brigimadlin BI 907828	E1/E2/E3 Enzyme MDM-2/p53	Cancer
Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase *MDM-2* inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research .

HY-10959

RG7112 20+ Cited Publications RO5045337	MDM-2/p53 E1/E2/E3 Enzyme	Neurological Disease Cancer
RG7112 is a potent, selective, orally active and blood-brain barrier crossed *MDM2-p53* inhibitor, with an IC₅₀ of 18 nM and a K_D of 11 nM for binding to MDM2 .

HY-12296

Navtemadlin 20+ Cited Publications AMG 232; KRT-232	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of *p53-MDM2* interaction, with an IC₅₀ of 0.6 nM. Navtemadlin binds to MDM2 with a K_d of 0.045 nM .

HY-101518

Alrizomadlin 4 Publications Verification APG-115; AA-115	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Alrizomadlin (APG-115) is an orally active *MDM2* protein inhibitor binding to MDM2 protein with IC₅₀ and K_i values of 3.8 nM and 1 nM, respectively . Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner .

HY-100892

MX69 2 Publications Verification	MDM-2/p53 IAP E1/E2/E3 Enzyme	Cancer
MX69 is an inhibitor of *MDM2/XIAP*, used for cancer treatment.

HY-18658

Siremadlin 10+ Cited Publications NVP-HDM201; HDM201	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Siremadlin (NVP-HDM201) is a potent, orally bioavailable and highly specific *p53-MDM2* interaction inhibitor.

HY-18986

SAR405838 3 Publications Verification MI-77301	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

HY-P4210

Sulanemadlin 1 Publications Verification ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-112816

MA242 1 Publications Verification	MDM-2/p53 Apoptosis	Cancer
MA242 is a specific dual inhibitor of *MDM2* and NFAT1. MA242 directly binds both MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated transcription of MDM2. MA242 induces apoptosis in pancreatic cancer cell lines regardless of p53 status .

HY-134823

MD-222 1 Publications Verification	MDM-2/p53 PROTACs E1/E2/E3 Enzyme	Cancer
MD-222 is the first-in-class highly potent PROTAC degrader of *MDM2. MD-222 consists of ligands for Cereblon* and *MDM2. MD-222 induces rapid degradation of the MDM2* protein and activation of wild-type p53 in cells. MD-222 has anticancer effects .

HY-128841

*PROTAC MDM2 Degrader-2* 1 Publications Verification	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-2 is an MDM2 PROTAC degrader. PROTAC MDM2 Degrader-2 can induce the self-ubiquitination and degradation of *MDM2, thereby upregulating the level of p53* protein. PROTAC MDM2 Degrader-2 has anti-tumor activity and can be used in the study of cancer . (Blue: MDM2 ligand (HY-128836); Black: linker (HY-128833))

HY-17493

MI-773 5+ Cited Publications	MDM-2/p53 Apoptosis	Neurological Disease Cancer
MI-773 is an orally active, selective MDM2-p53 interaction inhibitor with a K_i of 0.88 nM for MDM2. MI-773 blocks the *MDM2*-TP53 interaction. MI-773 potently activates p53. MI-773 induces Apoptosis. MI-773 causes tumor regression in xenograft models of adenoid cystic carcinoma. MI-773 exhibits anticancer effects in neuroblastoma. MI-773 TFA can be used for the research of adenoid cystic carcinoma .

HY-120086

RO-5963 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
RO-5963 is a dual *p53-MDM2* and p53-MDMX inhibitor with IC₅₀s of ~17 nM and ~24 nM, respectively .

HY-15997

(-)-U-50488 hydrochloride 1 Publications Verification (-)-Trans-(1S,2S)-U-50488 hydrochloride	Opioid Receptor	Infection Cancer
(-)-U-50488 hydrochloride ((-)-Trans-(1S,2S)-U-50488 hydrochloride) is a selective kappa-opioid receptor (KOR) agonist (b>K_d=2.2 nM) over μ-opioid receptor (MOR) (b>K_d=430 nM). (-)-U-50488 hydrochloride is a more active enantiomer than (+)?trans-(1R,2R) U-50488 (HY-15997A)?or the (±)?trans-racemic mixture U-50488 (HY-15997B). (-)-U-50488 hydrochloride has a potent and sustained anti-HIV effect in fected blood monocyte-derived macrophages (MDM) .

HY-169240

MX69-102	MDM-2/p53	Cancer
MX69-102 (compound MX69-102) is an *MDM-2/p53* inhibitor, inducing *MDM2* degradation, resulting in p53 activation and cancer cell apoptosis. MX69-102 shows effective inhibition on xenografted human MDM2-overexpressing ALL in SCID mice. .

HY-70027A

*p53 and MDM2 proteins-interaction-inhibitor dihydrochloride*	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-148833

MDM2-p53-IN-16	MDM-2/p53	Cancer
MDM2-p53-IN-16 is a *MDM2-p53* complex inhibitor with an IC₅₀ value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .

HY-163357

*CDK2/MDM2-IN-1*	CDK MDM-2/p53	Cancer
CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC₅₀ value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .

HY-128840

*PROTAC MDM2 Degrader-1*	PROTACs MDM-2/p53	Cancer
PROTAC MDM2 Degrader-1 (Compound 15a) is a MDM2 PROTAC degrader. The structures of both Linker ends of PROTAC MDM2 Degrader-1 are MDM2 ligands. PROTAC MDM2 Degrader-1 can not only block the binding of p53-MDM2, but also degrade the target MDM2 protein by utilizing the function of the E3 ligase of MDM2 itself, thus exerting an anti-tumor effect. (Pink: MDM2 ligand 2 (HY-128836); Black: Linker (HY-128844); Blue: E3 ligase Ligand 15 (HY-128836))

HY-128842

*PROTAC MDM2 Degrader-3* 1 Publications Verification	PROTACs MDM-2/p53	Cancer
PROTAC MDM2 Degrader-3 is a *MDM2* self-degrading (dimeric) PROTAC. PROTAC MDM2 Degrader-3 can be used in cancer research .

HY-15676A

Idasanutlin (enantiomer) RG7388 (enantiomer)	MDM-2/p53 Drug Isomer Apoptosis	Cancer
Idasanutlin enantiomer is the isomer of Idasanutlin (HY-15676), and can be used as an experimental control. Idasanutlin (RG7388) is a potent and selective *MDM2* antagonist, inhibiting p53-MDM2 binding, with an IC₅₀ of 6 nM.

HY-128843

*PROTAC MDM2 Degrader-4*	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-4 is a *MDM2* degrader based on PROTAC technology. PROTAC MDM2 Degrader-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase .

HY-W340839

*p53-MDM2-IN-1*	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-1 (Example 30) is an inhibitor of *p53-MDM2/X* protein interaction with an K_i value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .

HY-W340313

*p53-MDM2-IN-4*	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-4 (Example 4) is an inhibitor of *p53-MDM2/X* protein interaction, with a K_i value of 3.079 μM. p53-MDM2-IN-4 can be used in anti-tumor research .

HY-W097753

4-MDM 4-Methoxydiphenylmethane	Aminopeptidase	Others
4-MDM (4-Methoxydiphenylmethane) is an orally active anti-inflammatory compound that selectively enhances the Leukotriene A₄ Hydrolase (LTA₄H) aminopeptidase enzyme activity. 4-MDM reduces the neutrophil recruitment in the lung by enhancing the degradation of proline-glycine-proline by LTA₄H, thereby reducing inflammation, and does not affect the epoxy-hydrolase activity of LTA₄H. 4-MDM can be used for research on lung diseases .

HY-148106

MEL23	Ligands for E3 Ligase	Cancer
MEL23 is a MDM2 E3 ligase inhibitor that blocks the E3 ligase activity of the MDM2-MDMX complex. MEL23 inhibits Mdm2 and p53 ubiquitination in cells, reduce viability of cells with wild-type p53. MEL23 stabilizes MDM2 via a mechanism independent of p53 transcription .

HY-70027

*p53 and MDM2 proteins-interaction-inhibitor (chiral)*	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-123950

MMRi64	MDM-2/p53 Apoptosis	Cancer
MMRi64 disrupts *Mdm2-MdmX* interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces p53 accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research .

HY-14967

NSC 66811 1 Publications Verification	MDM-2/p53	Cancer
NSC 66811 is a *MDM2-p53* inhibitor, with a K_i of 120 nM for binding to MDM2 .

HY-158685

RG7112D	MDM-2/p53	Cancer
RG7112D is a potent *MDM2* inhibitor with IC₅₀s of 11 nM and >10000 nM and for MDM2-p53 and VHL-HIF1α by binding HTRF assay, respectively. RG7112D is coupled by an amide bond to VHL-Amine, resulting in a bi-functional molecule, YX-02-030. YX-02-03, a MDM2-PROTAC, potently inhibits MDM2-p53 binding (HTRF IC₅₀=63nM). RG7112D can stabilize MDM2 protein and increase p53 protein levels .

HY-124791

MMRi6	MDM-2/p53 PARP	Cancer
MMRi6 is a Mdm2-MdmX RING domain inhibitor that can disrupt Mdm2-MdmX RING-RING interaction in vitro. MMRi6 inhibits MdmX-stimulated *Mdm2* autoubiquitination and Mdm2-MdmX-mediated p53 polyubiquitination in vitro without affecting NEDD4-1 autoubiquitination. MMRi6 induces p53 stabilization and accumulation and induces PARP cleavage in wt-p53 Emu-myc lymphoma cells. MMRi6 inhibits the growth of wt-p53 and p53-null Emu-myc lymphoma cells with IC₅₀s of approximately 0.5 μM and 3 μM, respectively. MMRi6 can be used for the study of leukemia/lymphoma .

HY-133760

MI-888	MDM-2/p53	Cancer
MI-888 is an orally active *MDM2* inhibitor with a K_i of 0.44 nM. MI-888 can inhibit the *MDM2-p53* interaction. MI-888 has favorable pharmacokinetic properties and anti-tumor activity .

HY-149988

UNP-6457	MDM-2/p53	Cancer
UNP-6457 is a potent active *MDM2-p53* interaction inhibitor with an IC₅₀ values of 8.9 nM .

HY-12287

YH239-EE 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent.

HY-RS08264

MDM2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MDM2 Human Pre-designed siRNA Set A contains three designed siRNAs for MDM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MDM2 Human Pre-designed siRNA Set A MDM2 Human Pre-designed siRNA Set A

HY-RS08265

Mdm2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mdm2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mdm2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mdm2 Mouse Pre-designed siRNA Set A Mdm2 Mouse Pre-designed siRNA Set A

HY-123544

RDR03871	MDM-2/p53	Cancer
RDR03871 (compound 2) is a potent dual *MDM2/MDM4* inhibitor with IC₅₀ values of 35.4 nM and 10.4 nM for MDM2-p53 and MDM4-p53, respectively .

HY-149250

*MDMX/MDM2-IN-2*	MDM-2/p53 Apoptosis	Cancer
MDMX/MDM2-IN-2 is a potent *p53-MDM2/MDMX* dual inhibitors with K_is of 0.23 μM and 2.45 μM for MDM2 and MDMX, respectively. MDMX/MDM2-IN-2 inhibits the binding of p53 and MDM2 proteins. MDMX/MDM2-IN-2 restores the function of p53 and enables cell cycle arrest and apoptosis. MDMX/MDM2-IN-2 inhibits cell migration and invasion. MDMX/MDM2-IN-2 has antitumor activity .

HY-P0175A

740 Y-P TFA 740YPDGFR TFA; PDGFR 740Y-P TFA	PI3K Autophagy	Cancer
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

HY-18052

AM-8553	MDM-2/p53	Cancer
AM-8553 is a *MDM2/p53* inhibitor (K_D: 0.4 nM for MDM2). AM-8553 has anti-tumor activity

HY-124070

ISA 27	MDM-2/p53	Cancer
ISA 27 is a small-molecule *MDM2-p53* protein-protein interaction inhibitor. ISA 27 inhibits MDM2-mediated p53 ubiquitination and degradation. ISA 27 is promising for research of p53-mutant solid tumors (e.g., thyroid, breast cancer) .

HY-18331

MI-219	MDM-2/p53	Cancer
MI-219 is an antagonist for *MDM2* with a K_i of 13.3 μM. MI-219 inhibits the *MDM2-p53* interaction, inhibits thus the proliferation of FSCCL cells, with an IC₅₀ of 2.5 μM .

HY-150620

BI-0282	MDM-2/p53	Cancer
BI-0282 (Compound 1) is a potent *MDM2-p53* interaction inhibitor .

HY-170452

MDM2 ligand 4	MDM-2/p53 Ligands for Target Protein for PROTAC	Cancer
MDM2 ligand 4 is the ligand for *MDM2* that can be used for synthesis of PROTAC degrader KT-253 (HY-170451) .

HY-18658A

Siremadlin (R Enantiomer) NVP-HDM201 (R Enantiomer); HDM201 (R Enantiomer)	MDM-2/p53	Others
Siremadlin R Enantiomer (NVP-HDM201 R Enantiomer) is the R enantiomer of Siremadlin. Siremadlin is a potent and highly specific *MDM-2/p53* inhibitor.

HY-12941

AM-7209	MDM-2/p53	Cancer
AM-7209 is a potent and selective *MDM2-p53* interaction inhibitor with a K_d of 38 pM. AM-7209 inhibits the MDM2 amplified SJSA-1 osteosarcoma cell line with an IC₅₀ of 1.6 nM. AM-7209 shows antitumor activities .

HY-178036

ZM484	MDM-2/p53 Topoisomerase Bcl-2 Family Caspase Cyclin G-associated Kinase (GAK)	Cancer
ZM484 is a potent dual *p53-MDM2/TOP1* inhibitor that exhibits antiproliferative and antitumor activity both in vitro and in vivo. ZM484 effectively upregulates p53 and MDM2 proteins and maintains TOP1 inhibitory activity by the release of camptothecin (CPT) and a potent p53-MDM2 inhibitor. ZM484 induces cell cycle arrest and apoptosis by regulating the expression of key apoptosis- and cycle-related proteins, including caspase-3, Bcl-2, and Cyclin B1. ZM484 can be used for colorectal cancer research .

Cat. No.	Product Name

HY-L128

E3 Ligase Ligand Library

174 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation.

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 174 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

HY-L003

Apoptosis Compound Library

3,407 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 3,407 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

HY-L109

Protein-protein Interaction Inhibitor Library

782 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 782 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-P0175

740 Y-P 240+ Cited Publications 740YPDGFR; PDGFR 740Y-P	PI3K Autophagy	Cancer
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

HY-P4210

Sulanemadlin 1 Publications Verification ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-P3509

PNC-28	MDM-2/p53	Cancer
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research .

HY-141584

ATSP-7041	MDM-2/p53	Cancer
ATSP-7041, a selective dual peptide inhibitor of *MDM2* and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .

HY-P3509A

PNC-28 acetate	MDM-2/p53	Cancer
PNC-28 acetate is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 acetate can be used for pancreatic cancer research .

HY-P1755

p53 (17-26)	MDM-2/p53	Cancer
p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a K_d of 50 nM for *MDM2*. p53 (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer .

HY-106263B

Tyroserleutide hydrochloride	PTEN PDK-1 MDM-2/p53 Apoptosis Akt	Cancer
Tyroserleutide hydrochloride is a tripeptide isolated from the degradation products of porcine spleen with antitumor activity. Tyroserleutide hydrochloride can upregulate the expression of the tumor suppressor gene PTEN and inhibit the activity of AKT and PDK1. Tyroserleutide hydrochloride inhibits tumor cell proliferation and MDM2 phosphorylation by inhibiting the PI3K/AKT pathway, and also upregulates P21, P27, P53, and induces mitochondrial damage and cell apoptosis .

HY-P1755F

p53 (17-26), FITC labeled	MDM-2/p53	Cancer
p53 (17-26), FITC labeled is a biological active peptide. p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a K_d of 50 nM for *MDM2*. p53 (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer.

HY-P5367

5-FAM-PMDM6 PMDM6-F	Fluorescent Dye	Others
5-FAM-PMDM6 (PMDM6-F) is a biological active peptide. (PMDM6-F is a fluorescent-labeled probe for MDM2-binding assay.)

HY-P11256

pDI	MDM-2/p53	Cancer
pDI is a peptide. pDI inhibits *MDM2-p53* and MDMX-p53 interactions with IC₅₀s of 10 and 100 nM respectively. pDI can be used in the research of colorectal cancer .

HY-P1755A

p53 (17-26) acetate	MDM-2/p53	Cancer
p53 (17-26) acetate is a peptide derived from the P53 MDM2 binding domain, with a K_d of 50 nM for *MDM2*. p53 (17-26) acetate causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) acetate exhibits antitumor activity and is applicable to research related to pancreatic cancer .

HY-P0175A

740 Y-P TFA 740YPDGFR TFA; PDGFR 740Y-P TFA	PI3K Autophagy	Cancer
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

HY-P11255

SPDI-48-T1	MDM-2/p53	Cancer
SPDI-48-T1 is a lysine-stapled peptide. SPDI-48-T1 exhibits discernible binding affinities for *MDM2* and MDMX, with K_d values of 396 nM and 456 nM, respectively. SPDI-48-T1 exhibits anticancer activity against breast cancer, colorectal cancer, non-small cell lung cancer, cervical cancer, and malignant melanoma .

HY-P5930

HOXB7 8–25 MDM2 32-46	Ligands for E3 Ligase	Cancer
HOXB7 8–25 (MDM2 32-46) is an *MDM2*-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 ⁺ T cell responses .

HY-P10286

Phage-derived 12/1 peptide	MDM-2/p53	Cancer
Phage-derived 12/1 peptide exhibits antitumor activity by targeting *MDM2* and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC₅₀ of 0.15 and 1.25 μM .

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for *MDM2* and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .

HY-P11490

DPMI-ω	MDM-2/p53	Inflammation/Immunology Cancer
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins *MDM2* and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 ⁺/CD8 ⁺ cytotoxic T cells and suppressing CD4 ⁺/CD25 ⁺ regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .

HY-P11635

ATSP-7342	Drug Derivative MDM-2/p53	Cancer
ATSP-7342 is a negative control analog of ATSP-7041. ATSP-7342 exhibits lower binding affinity to both *MDM2* (K_i = 536 nM) and MDMX (K_i >1000 nM), compared with ATSP-7041 .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991314

NMC-001	MDM-2/p53	Cancer
NMC-001 is a human IgG1 monoclonal antibody (mAb) targeting *MDM2*. NMC-001 can be used in pancreatic cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992431

OM-301	MDM-2/p53	Inflammation/Immunology
OM-301 is a human monoclonal antibody that targets *MDM2*.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0068

Solasodine 5 Publications Verification Purapuridine; Solancarpidine; Solasodin	Infection Cardiovascular Disease Alkaloids Piperidine Alkaloids Neurological Disease Classification of Application Fields Solanum nigrum Linn. Solanaceae Plants Inflammation/Immunology Disease Research Fields Source Classification	MDM-2/p53 Fungal E1/E2/E3 Enzyme Apoptosis
Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine induces apoptosis by inhibiting the p53-MDM2 complex, p21Waf1/Cip1, and Bcl-2 proteins. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities .

HY-N7012

7,3',4'-Tri-O-methylluteolin 1 Publications Verification 5-Hydroxy-3',4',7-trimethoxyflavone	Monophenols Flavonoids Classification of Application Fields Flavones Labiatae Phenols Plants Swartzia polyphylla DC. Inflammation/Immunology Disease Research Fields Source Classification	Lipoxygenase TNF Receptor Interleukin Related COX Fungal Parasite Apoptosis
7,3',4'-Tri-O-methylluteolin (5-Hydroxy-3',4',7-trimethoxyflavone) is a flavonoid with multiple biological activities. 7,3',4'-Tri-O-methylluteolin inhibits soybean lipoxygenase (LOX), with an IC₅₀ value of 23.97 µg/mL. 7,3',4'-Tri-O-methylluteolin possesses anti-inflammatory effects in Lipopolysaccharides (HY-D1056) (LPS)-induced RAW 264.7 macrophages. 7,3',4'-Tri-O-methylluteolin inhibits the binding of MDM2 with p53 and induces apoptosis in MCF-7 breast cancer cells. 7,3',4'-Tri-O-methylluteolin also has antioxidant, antifungal and antitrypanosomal activities sup>[4]sup>[5].

HY-N12768

Rhodojaponin VI	Structural Classification Terpenoids Diterpenoids Pieris japonica (Thunb.) D. Don ex G. Don Ericaceae Plants Source Classification	MDM-2/p53 Notch Calcium Channel
Rhodojaponin VI is an orally active diterpenoid compound found in hododendron molle G. Don (Ericaceae) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the *MDM2-Notch1* signalling pathway by reducing *MDM2* and Notch1 expression. Rhodojaponin VI indirectly reduces Cav_2.2 current intensity by inhibiting NSF-mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain .

Cat. No.	Product Name	Chemical Structure

HY-153939S

Idasanutlin-d3-1
Idasanutlin-d₃-1 (RG7388-d₃-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of *MDM2/p53*. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia .

HY-12296S

Navtemadlin-d7
Navtemadlin-d₇ is the deuterium labeled Navtemadlin. Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC₅₀ of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM .

HY-18986S

SAR405838-d10
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

HY-W704348

Diphenyltin Dichloride-d10
Diphenyltin Dichloride-d₁₀ is the deuterium labeled NSC405640 (HY-144105). NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .

Cat. No.	Product Name		Classification

HY-114312

MD-224 5+ Cited Publications		PROTAC Synthesis
MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (MDM2) degrader based on the proteolysistargeting chimera (PROTAC) concept. MD-224 consists of ligands for Cereblon and *MDM2. MD-224 induces rapid degradation of MDM2 at concentrations <1 nM in human leukemia cells, and achieves an IC₅₀* value of 1.5 nM in inhibition of growth of RS4;11 cells. MD-224 has the potential to be a new class of anticancer agent . MD-224 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-128832

Nutlin-C1-amido-PEG4-C2-N3 MDM2 Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 48		Azide
Nutlin-C1-amido-PEG4-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Nutlin 3 based MDM2 ligand and 4-unit PEG linker used in PROTAC technology. Nutlin-C1-amido-PEG4-C2-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-181358

(4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3		Azide
(4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (4R,5S)-Nutlin carboxylic acid based MDM2 ligand and a linker used in PROTAC technology. (4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3 can be connected to the ligand for protein by a linker to form PROTAC EZH2 Degrader-29 (HY-181357) .

HY-180924

(4R,5S)-Nutlin carboxylic acid-NHC2-PEG2-N3		Azide
(4R,5S)-Nutlin carboxylic acid-NHC2-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (4R,5S)-Nutlin carboxylic acid based MDM2 ligand and a linker used in PROTAC technology. (4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3 can be connected to the ligand for protein by a linker to form PROTAC EZH2 Degrader-30 (HY-181359) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks